Benefit of medication reviews by renal pharmacists in the setting of a computerized physician order entry system with clinical decision support. (22nd July 2022)

• Record Type: Journal Article
• Authors: Seiberth, Sarah; Mannell, Hanna; Birkenmaier, Christof; Neuerburg, Carl; Smolka, Vera; Andraschko, Monika; Strobach, Dorothea
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 47:Number 10(2022)
• Page Start: 1531
• Page End: 1538
• Publication Date: 2022-07-22
• Subjects: CPOE‐CDS‐system -- drug‐related problems -- pharmacist‐led medication review -- renal impairment -- renal pharmacist; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.13697
• Languages: English
• ISSNs: 0269-4727

Abstract

Abstract: What Is Known and Objective: A 'renal pharmacist consultant service' (RPCS) reviewing patients' charts with renal impairment (RI) for drug‐related problems (DRP) can foster patient safety. However, the benefit of this service in the new setting of a computerized physician order entry (CPOE)‐system with a clinical decision support (CDS)‐system is unknown. The aim of our study was to evaluate the general need for an RPCS on wards with a CPOE‐CDS‐system already in use and its effectiveness on prescription changes to ensure in‐hospital patient safety. Methods: Over a period of 3 months (02‐04/2021), elective orthopaedic and trauma patients with eGFRabsolute /CrCl <60 ml/min at a German University Hospital received a medication review by a renal pharmacist for all medication entered into the CPOE‐system (Meona®) by the treating physicians. Written consultations explaining identified DRP and recommending interventions to solve them, for example, dose or drug adaptation, were shared with the physicians directly in the drug chart tab of Meona®. In complex cases, DRP were additionally discussed via phone. The prescription changes were evaluated retrospectively. Results and Discussion: During 53 working days, 712 (30.5%) of 2331 screened patients were included with an eGFRnon‐indexed /CrCl <60 ml/min and a pharmacist‐led medication review was performed for all medication presented in the CPOE‐system (Meona®). In 79 of 712 (11.1%) patients, one or more DRP were detected (median 1 DRP (1–3) per patient) and written recommendations concerning 106 of 1090 (9.7%) drugs were shared via Meona®. In total, 104 DRP were identified, mostly caused by 'dosage too high' ( n = 55, 52.9%), 'dosage regime wrong' ( n = 13, 12.5%), and 'contraindication' ( n = 9, 8.7%). Acceptance rate of recommendations was 74.0% ( n = 77/104). In nine cases (8.7%), despite of specific recommendations, no adjustment of drugs was made because of lack of alternatives. In 11 (10.6%) cases, prescription remained unchanged for unknown reasons and in seven (6.7%) cases, the result was unknown due to discharge. What Is New and Conclusion: In the setting of prescribing in a CPOE‐CDS‐system, that provides physicians with advice for drug or dose adaption, the pharmacist‐led medication reviews still identified DRP in orthopaedic and trauma patients with RI. A RPCS forwarding recommendations to solve DRP via the electronic medical record increased appropriate prescribing by physicians and, thus, may further improve patient safety. Abstract : After implementing a computerized physician order entry (CPOE)system with clinical decision support (CDS), that provides physicians with advice for drug or dose adaption during the prescription process, drug related problems (DRP) were still identified by a renal pharmacist in 11% of the medication reviews of elective orthopaedic and trauma patients with renal impairment. Following renal pharmacist's interventions by forwarding recommendations to solve DRP via the electronic medical record, 74% of inappropriate prescriptions were adjusted by physicians.